相似文献
1
Cancer: crossing over to drug resistance.
Nature. 2008 Feb 28;451(7182):1066-7. doi: 10.1038/4511066a.
2
PARP inhibitors: will the new class of drugs match the hype?
J Natl Cancer Inst. 2009 Sep 16;101(18):1230-2. doi: 10.1093/jnci/djp315. Epub 2009 Sep 8.
3
An Achilles' heel for breast cancer?
Nat Struct Mol Biol. 2005 May;12(5):387-8. doi: 10.1038/nsmb0505-387.
4
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.
5
[Role of oncogenetics in the treatment of breast and ovarian cancer].
Orv Hetil. 2011 Jul 24;152(30):1214-5. doi: 10.1556/OH.2011.30M.
6
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.
7
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.
8
PARP inhibitors: targeting the right patients.
J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
9
[PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Rev Med Suisse. 2011 May 25;7(296):1137-40.
10
PARP inhibition in BRCA-mutated breast and ovarian cancers.
Lancet. 2010 Jul 24;376(9737):211-3. doi: 10.1016/S0140-6736(10)61119-1.
引用本文的文献
1
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
J Ovarian Res. 2021 Jun 21;14(1):80. doi: 10.1186/s13048-021-00831-y.
2
Multimodal delivery of irinotecan from microparticles with two distinct compartments.
J Control Release. 2013 Nov 28;172(1):239-245. doi: 10.1016/j.jconrel.2013.08.017. Epub 2013 Aug 23.
3
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.
Am J Cancer Res. 2011;1(3):301-327. Epub 2010 Jan 3.
4
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
Breast Cancer Res. 2010;12(2):R17. doi: 10.1186/bcr2486. Epub 2010 Mar 5.
5
Genetic characterization of breast cancer and implications for clinical management.
J Cell Mol Med. 2009 Oct;13(10):4090-103. doi: 10.1111/j.1582-4934.2009.00906.x. Epub 2009 Sep 14.
6
Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer.
Nat Rev Clin Oncol. 2009 Aug;6(8):488-92. doi: 10.1038/nrclinonc.2009.90.
7
Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.
Int J Cancer. 2009 Apr 1;124(7):1700-6. doi: 10.1002/ijc.24104.
Zotero 插件